Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Breeze Holdings Acquisition (BREZU)
Upcoming IPO
AMMO (POWW)
Vision Marine Technologies (VMAR)
Spring Valley Acquisition (SVSVU)
Genesis Park Acquisition (GNPK.U)
Ozon Holdings Plc (OZON)
Tiga Acquisition (TINVU)
Spartan Acquisition Corp. II (SPRQ.U)
Priced IPO
Sotera Health Company (SHC)
Maravai LifeSciences Holdings, Inc. (MRVI)
Telos Corporation (TLS)
NeoGames S.A (NGMS)
Olema Pharmaceuticals, Inc. (OLMA)
Yatsen Holding Limited (YSG)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
More companies

Atea Pharmaceuticals, Inc. (AVIR)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Leveraging their deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, they have built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, they are focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, the virus that causes COVID-19, hepatitis C virus, or HCV, dengue virus, and respiratory syncytial virus, or RSV. They believe their team’s expertise from decades of developing innovative antiviral treatments uniquely positions them to advance medicines that have the potential to cure some of the world’s most severe viral diseases by inhibiting the enzymes central to viral replication.All of their product candidates have been discovered and developed internally and they retain full global rights to commercialize their product candidates.
Industry
Pharmaceuticals
CEO CFO
Jean-Pierre Sommadossi Andrea Corcoran
Employees Founded
19 2014

Contacts

Address: 125 Summer Street Boston, MA 02110

Telephone: (857) 284-8891

Web page: http://www.ateapharma.com

IPO information

Expected Date 10/30/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $1822.52
Revenues (MM) $0
Net Income (Loss) (MM) $-22.3

Voting

What do you think will happen with the AVIR share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 11
Shares Revised (MM) 12.5
Expected offer amount (MM) $253
Realized offer amount(MM) $300
Underwriters
JP Morgan/ Morgan Stanley/ Evercore ISI/ William Blair
CO-Managers
-

Sector: Healthcare

Tweets about $AVIR

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats